Man Reading Newspaper

News

Latest news regarding ScientificMed and our digital therapeutics.

Rectangle 178.png

ScientificMed, together with researchers and clinicians from three hospitals in Stockholm, has been granted funding from the Swedish Breast Cancer Association (Bröstcancerförbundet) for a clinical trial (RCT) targeting women with endocrine adjuvant therapy breast cancer.


The purpose of the RCT is to study whether using a Digital Therapeutic (DTx) as support increase adherence to adjuvant endocrine therapy, reduce the late effects of treatment and increase quality of life. The secondary aims are to study health economic effects, compliance to usage of the app and its perceived usability.


For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00.

ScientificMed in collaboration with leading Nordic hospitals and a pharmaceutical company has developed a patient app (Digital Therapeutics, DTx) to support prostate cancer patients undergoing antihormone therapy. The app supports the patients with a targeted exercise program in order to counteract side effects of the therapy.

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00

Positive study results with a digital therapeutic (DTx) for breast cancer patients published in Supportive Care in Cancer


The pilot study "Patient interactive digital support for women with adjuvant endocrine therapy in order to increase compliance and quality of life" showed the app was perceived easy to use and of support in every-day life of breast cancer survivors. The patients especially appreciated the possibility to overview their reported symptoms over time in relation to their activities and physical exercise.

The primary aim of the study was to develop and investigate a patient interactive digital support (app) for patients on adjuvant endocrine breast cancer treatment. The project to develop the solution was a joint venture between the Capio St Görans hospital, ScientificMed, AstraZeneca and Novartis Sweden. It was supported with grants from the Region of Stockholm Innovation fund and with a sponsorship agreement from Novartis and AstraZeneca.

View Supportive Care in Cancer

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00

blue.png

© 2020 by ScientificMed Tech AB

ScientificMed Tech AB

Surbrunnsgatan 44A

SE-113 48 Stockholm, Sweden

info@scientificmed.com

LI-Logo.png